Related Experiment Video

Updated: Aug 31, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K

Effect of AKT silence on malignant biological behavior of renal cell carcinoma cells

Zuan Li1, DeYong Nong1, Bincai Li1

  • 1Department of Urology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

BMC Urology
|August 22, 2022
PubMed
Abstract

Insights

Silencing AKT in renal cell carcinoma (RCC) cells inhibited proliferation, invasion, and migration while promoting apoptosis. These findings suggest AKT is a potential therapeutic target for treating this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Renal cell carcinoma (RCC) is a highly invasive malignancy with significant mortality.
  • The AKT signaling pathway plays a crucial role in cellular processes and is a target for RCC treatment.

Purpose of the Study:

  • To investigate the impact of AKT gene silencing on the malignant behaviors of renal cell carcinoma cells.

Main Methods:

  • Immunohistochemistry to quantify AKT expression in tumor and normal tissues.
  • RT-qPCR and Western blot to select optimal siRNA for AKT silencing in Caki-2 cells.
  • Cell proliferation, invasion, migration, and apoptosis assays (CCK8, Transwell, scratch, flow cytometry) to assess the effects of AKT silencing.

Main Results:

  • Successful silencing of AKT in Caki-2 cells was confirmed.
  • AKT silencing significantly inhibited cell proliferation, invasion, and migration.
  • AKT silencing promoted apoptosis and prevented cell cycle progression from G1 to S phase in RCC cells.
  • Immunohistochemical analysis showed differential AKT1 expression in RCC tissues compared to normal tissues.

Conclusions:

  • AKT silencing effectively suppresses malignant behaviors of renal cell carcinoma cells.
  • AKT plays a role in the malignant growth of RCC and represents a potential therapeutic target.
  • Targeting AKT may offer a novel strategy for RCC treatment.
Keywords:
AKTBiological behaviorRenal cell carcinomaSilence

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.1K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K